10.09.19
Hugh Davis, chief business officer at Frontage Laboratories, talks about the CRO's range of services and its expansion into biologics and early development capabilities.
Related Breaking News
-
Breaking News | Financial Reports
Veklury Drives 2Q Growth for Gilead
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.07.30.21
-
Financial Reports
AbbVie's 2Q Revenue up 34%
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.07.30.21
-
Breaking News | Financial Reports
BMS 2Q Revenues up 16%
Top sellers Revlimid, Eliquis and Opdivo drive growth while established brands were down 64%.07.30.21
-
Breaking News | Trials & Filings
Janssen's UPTRAVI IV FDA-Approved for PAH
New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.07.30.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028
Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.07.30.21
-
Financial Reports
J&J's 2Q Pharma Sales Up 17%
STELARA and DARZALEX sales drive growth with sales up 34% to $2.3 billion and up 59% to $1.4 billion in the quarter, respectively.07.29.21
-
Breaking News | Financial Reports
Pfizer's 2Q Revenues Up 92%
COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.07.29.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
CellCAN and CCRM Partner to Launch CATTI
New Institute will tackle gaps in training Canada’s GMP workforce.07.29.21
-
Breaking News | Facilities | Industry News
Regeneron Investing $1.8B in Tarrytown, NY Campus
New York's largest biotech company creating an additional 1,000 jobs over five years.07.29.21
-
Breaking News | Facilities | Industry News
Nexus Pharmaceuticals Opens State-of-the-Art Manufacturing Facility
Phase I investment of $100 million supports a new three-story manufacturing facility.07.29.21
-
Breaking News | Facilities | Industry News
Celanese Opens Pharma Drug Delivery Feasibility Lab
State-of-the-art R&D lab at Florence, KY site expands technical feasibility capabilities for long-acting delivery of small molecules, biologics and nucleotides.07.29.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Akston Biosciences, Seppic Ink Commercial Supply Agreement
Deal is for an adjuvant to formulate shelf-stable COVID-19 vaccine at global scale.07.29.21
-
Bio News | Biosimilars | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Abzena, BioXpress Therapeutics Enter Biosimilar Tie-up
Partnership to support the development and manufacture of biosimilars for global customers.07.29.21
-
Breaking News | Industry News | Promotions & Moves
SCA Pharma Names Scott Luce as CEO
Luce’s priorities include serving new customer segments and fulfilling the company’s ambitious construction plan to expand capacity.07.29.21
-
Breaking News | Industry News | Promotions & Moves
Sterling Pharma Solutions Appoints Ian Baxendale to Lead Team at Dudley, UK Site
Baxendale has over 20 years of academic and industrial experience within organic synthesis.07.29.21
